Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONJUPRI vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective vasopressin V1a receptor antagonist, inhibiting vasopressin-mediated smooth muscle contraction in arterioles, leading to vasodilation and reduced portal pressure.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Hepatorenal syndrome type 1 with rapidly worsening renal function
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Adults: Initial 10 mg orally once daily, titrate to 20-40 mg once daily. Maximum 40 mg/day.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 9-16 hours (mean 12 hours) in healthy volunteers, supporting once-daily dosing. Half-life may be prolonged in patients with mild-to-moderate hepatic impairment.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Primarily hepatic via CYP3A4 and CYP2C19; minor renal excretion.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Primarily hepatic metabolism via CYP3A4, with 80-90% excreted as metabolites in feces (biliary) and 10-20% in urine as unchanged drug or metabolites.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Volume of distribution is approximately 50 L (0.7-1.0 L/kg), indicating extensive extravascular distribution. High Vd suggests significant tissue binding.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Absolute bioavailability is approximately 30% (range 20-40%) due to extensive first-pass metabolism. Food does not significantly affect bioavailability.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
e GFR 30-60 m L/min: No adjustment; e GFR <30 m L/min: Not recommended (insufficient data).
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Child-Pugh A (mild): No adjustment; Child-Pugh B or C: Contraindicated.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Safety and efficacy not established in pediatric patients.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Start at lower end of dosing range (10 mg daily) due to increased sensitivity; monitor renal function.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
WARNING: RISK OF SERIOUS HYPOTENSION AND HYPOVOLEMIA. Monitor hemodynamics closely; discontinue or adjust dose if hypotension occurs.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Hypotension/Hypovolemia,Cardiac ischemia,Electrolyte imbalances (hyperkalemia, hyponatremia),Hepatic encephalopathy,Monitor renal function and blood pressure
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypersensitivity to conivaptan or any component,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Take with food to reduce GI upset. Avoid alcohol as it may increase hepatotoxicity risk.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Conjupri (levamlodipine) is an S-enantiomer of amlodipine. Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, calcium channel blockers may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension. Risk in first trimester is low; second/third trimester: potential fetal risks include reduced uteroplacental perfusion, fetal distress, and neonatal hypotension. Use only if maternal benefit outweighs fetal risk.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Excreted in human milk; estimated infant dose <5% of maternal weight-adjusted dose; M/P ratio not established. No adverse effects reported in infants. American Academy of Pediatrics considers amlodipine compatible with breastfeeding. Monitor infant for hypotension and bradycardia.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
No specific dose adjustments recommended for pregnancy. However, due to increased plasma volume and cardiac output, higher doses may be required to achieve therapeutic effect. Start at lowest effective dose and titrate based on blood pressure response. Close monitoring for hypotension is essential as vasodilation may be exaggerated.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
CONJUPRI (levoketoconazole) is a potent CYP3A4 inhibitor; avoid coadministration with sensitive CYP3A4 substrates. Monitor liver function tests monthly due to hepatotoxicity risk. QT prolongation risk: obtain baseline ECG and monitor electrolytes. Adjust dose in hepatic impairment; contraindicated in Child-Pugh B/C. Taper dose if discontinuing after prolonged use to avoid adrenal insufficiency.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take exactly as prescribed; do not stop without consulting your doctor.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea.,Avoid grapefruit and grapefruit juice while taking this medication.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Use effective contraception if of childbearing potential; this drug can harm unborn baby.,Do not take with certain other medications; provide a complete list to your doctor.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONJUPRI vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
CONJUPRI is a Estrogen Replacement that works by Selective vasopressin V1a receptor antagonist, inhibiting vasopressin-mediated smooth muscle contraction in arterioles, leading to vasodilation and reduced portal pressure.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONJUPRI and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONJUPRI is: Adults: Initial 10 mg orally once daily, titrate to 20-40 mg once daily. Maximum 40 mg/day.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONJUPRI and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONJUPRI is classified as Category C. Conjupri (levamlodipine) is an S-enantiomer of amlodipine. Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, calcium channel blockers. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.